{"doi":"10.1101/2020.08.07.20169961","title":"Neutralizing antibody response in non-hospitalized SARS-CoV-2 patients","abstract":"<jats:title>Abstract</jats:title>\n                <jats:p>The majority of infections with SARS-CoV-2 are asymptomatic or mild without the necessity of hospitalization. It is of importance to reveal if these patients develop an antibody response against SARS-CoV-2 and to define which antibodies confer virus neutralization. We conducted a comprehensive serological survey of 49 patients with a mild course of disease and quantified neutralizing antibody responses against a clinical SARS-CoV-2 isolate employing human cells as targets.</jats:p>\n                <jats:p>Four patients (8%), even though symptomatic, did not develop antibodies against SARS-CoV-2 and two other patients (4%) were only positive in one of the six serological assays employed. For the remainder, antibody response against the S-protein correlated with serum neutralization whereas antibodies against the nucleocapsid were poor predictors of virus neutralization. Regarding neutralization, only six patients (12%) could be classified as highly neutralizers. Furthermore, sera from several individuals with fairly high antibody levels had only poor neutralizing activity. In addition, employing a novel serological Western blot system to characterize antibody responses against seasonal coronaviruses, we found that antibodies against the seasonal coronavirus 229E might contribute to SARS-CoV-2 neutralization.</jats:p>\n                <jats:p>Altogether, we show that there is a wide breadth of antibody responses against SARS-CoV-2 in patients that differentially correlate with virus neutralization. This highlights the difficulty to define reliable surrogate markers for immunity against SARS-CoV-2.</jats:p>","journal":"medRxiv","year":null,"id":21650,"datarank":0.834409984120889,"base_score":2.302585092994046,"endowment":2.302585092994046,"self_citation_contribution":0.3453877639491069,"citation_network_contribution":0.489022220171782,"self_endowment_contribution":0.3453877639491069,"citer_contribution":0.489022220171782,"corpus_percentile":null,"corpus_rank":null,"citation_count":9,"citer_count":8,"citers_with_citation_signal":8,"citers_with_endowment":8,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":138623,"name":"Ramona Businger","orcid":null,"position":1,"is_corresponding":false},{"id":138625,"name":"Karina Althaus","orcid":null,"position":2,"is_corresponding":false},{"id":138628,"name":"Simon Fink","orcid":null,"position":3,"is_corresponding":false},{"id":138630,"name":"Felix Ruoff","orcid":null,"position":4,"is_corresponding":false},{"id":138631,"name":"Klaus Hamprecht","orcid":null,"position":5,"is_corresponding":false},{"id":138632,"name":"Bertram Flehmig","orcid":null,"position":6,"is_corresponding":false},{"id":138633,"name":"Tamam Bakchoul","orcid":null,"position":7,"is_corresponding":false},{"id":138634,"name":"Markus F. Templin","orcid":null,"position":8,"is_corresponding":false},{"id":138635,"name":"Michael Schindler","orcid":null,"position":9,"is_corresponding":false},{"id":138621,"name":"Natalia Ruetalo","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":2.302585092994046,"endowment":2.302585092994046,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"21071399","pmcid":null,"openalex_id":"https://openalex.org/W3047706242","authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[{"year":2021,"count":8},{"year":2022,"count":1}],"oa_status":"green","license":"cc-by-nc-nd","oa_locations":[{"url":"https://www.medrxiv.org/content/medrxiv/early/2020/09/22/2020.08.07.20169961.full.pdf","host_type":"repository"},{"url":"https://doi.org/10.1128/msphere.01145-20","host_type":"GREEN"},{"url":"https://www.medrxiv.org/content/medrxiv/early/2020/09/22/2020.08.07.20169961.full.pdf","host_type":"repository"},{"url":"https://syndication.highwire.org/content/doi/10.1101/2020.08.07.20169961","host_type":"publisher"},{"url":"https://doi.org/10.1101/2020.08.07.20169961","host_type":"repository"},{"url":"https://europepmc.org/article/PPR/PPR197702","host_type":"Europe_PMC"},{"url":"https://europepmc.org/api/fulltextRepo?pprId=PPR197702&type=FILE&fileName=EMS91145-pdf.pdf&mimeType=application/pdf","host_type":"Europe_PMC"}],"fields_of_study":["SARS-CoV-2 and COVID-19 Research","COVID-19 Clinical Research Studies","SARS-CoV-2 detection and testing","Medicine"],"mesh_terms":[],"keywords":["Neutralization","Antibody","Serology","Virology","Asymptomatic","Neutralizing antibody","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","Immunology","Medicine","Virus","Antibody response","Coronavirus disease 2019 (COVID-19)","Biology","Disease","Infectious disease (medical specialty)","Internal medicine"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-06-06T16:27:42.599209Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}